Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival

Autor: Aruni S. Arachchige-Don, Mary C. Horne, Tommaso Patriarchi, Michaela S. Donaldson, Maike Zimmermann
Rok vydání: 2016
Předmět:
0301 basic medicine
Cell cycle checkpoint
Estrogen receptor
Pharmacology
Retinoblastoma Protein
Estrogen Deprivation
0302 clinical medicine
Receptors
Insulin
Phosphorylation
Extracellular Signal-Regulated MAP Kinases
Fulvestrant
Cancer
Cell Cycle Arrest
Tumor
Estradiol
biology
Retinoblastoma protein
Cell cycle
Metformin
Cyclin-Dependent Kinases
MEK
Up-Regulation
Protein Transport
Receptors
Estrogen

Local
Gene Knockdown Techniques
030220 oncology & carcinogenesis
RNA Interference
Female
Signal transduction
Signal Transduction
medicine.drug
Cyclin G2
Tamoxifen-Resistant
Breast Neoplasms
Disease-Free Survival
Cell Line
03 medical and health sciences
Cyclin D1
Cyclin-dependent kinase
Cell Line
Tumor

Report
Breast Cancer
medicine
Humans
RAF/MEK/MAPK pathway
Molecular Biology
Cell Nucleus
Mitogen-Activated Protein Kinase Kinases
Estrogens
MAPK pathway
Cell Cycle Checkpoints
RAF
Cell Biology
Estrogen
Survival Analysis
CCNG2
Proto-Oncogene Proteins c-raf
Neoplasm Recurrence
030104 developmental biology
biology.protein
Cancer research
Biochemistry and Cell Biology
Neoplasm Recurrence
Local

IGF-1R
CDK10
Developmental Biology
Zdroj: Cell cycle (Georgetown, Tex.), vol 15, iss 23
ISSN: 1551-4005
1538-4101
Popis: Definition of cell cycle control proteins that modify tumor cell resistance to estrogen (E2) signaling antagonists could inform clinical choice for estrogen receptor positive (ER+) breast cancer (BC) therapy. Cyclin G2 (CycG2) is upregulated during cell cycle arrest responses to cellular stresses and growth inhibitory signals and its gene, CCNG2, is directly repressed by E2-bound ER complexes. Our previous studies showed that blockade of HER2, PI3K and mTOR signaling upregulates CycG2 expression in HER2+ BC cells, and that CycG2 overexpression induces cell cycle arrest. Moreover, insulin and insulin-like growth factor-1 (IGF-1) receptor signaling strongly represses CycG2. Here we show that blockade of ER-signaling in MCF7 and T47D BC cell lines enhances the expression and nuclear localization of CycG2. Knockdown of CycG2 attenuated the cell cycle arrest response of E2-depleted and fulvestrant treated MCF7 cells. These muted responses were accompanied by sustained inhibitory phosphorylation of retinoblastoma (RB) protein, expression of cyclin D1, phospho-activation of ERK1/2 and MEK1/2 and expression of cRaf. Our work indicates that CycG2 can form complexes with CDK10, a CDK linked to modulation of RAF/MEK/MAPK signaling and tamoxifen resistance. We determined that metformin upregulates CycG2 and potentiates fulvestrant-induced CycG2 expression and cell cycle arrest. CycG2 knockdown blunts the enhanced anti-proliferative effect of metformin on fulvestrant treated cells. Meta-analysis of BC tumor microarrays indicates that CCNG2 expression is low in aggressive, poor-prognosis BC and that high CCNG2 expression correlates with longer periods of patient survival. Together these findings indicate that CycG2 contributes to signaling networks that limit BC.
Databáze: OpenAIRE